5
Participants
Start Date
July 31, 2014
Primary Completion Date
September 30, 2015
Study Completion Date
September 30, 2015
AAV1/SERCA2a
AAV1/SERCA2a will be delivered by a percutaneous method in the catheter laboratory. Dose: 1x 10\^13 DRP (DNase resistant particles)
Placebo
Placebo aliquots will be of the same composition as the investigational medicinal product with the absence of the active ingredient and will be visually indistinguishable from the medicinal product. Placebo is prepared and handled exactly as above in a blinded fashion.
Papworth Hospital, Cambridge
Harefield Hospital, Royal Brompton and Harefiled NHS Trust, Middlesex
Collaborators (2)
British Heart Foundation
OTHER
Leducq Foundation
OTHER
Celladon Corporation
INDUSTRY
Imperial College London
OTHER